These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25294428)

  • 1. Selection and characterization of llama single domain antibodies against N-terminal huntingtin.
    Schut MH; Pepers BA; Klooster R; van der Maarel SM; El Khatabi M; Verrips T; den Dunnen JT; van Ommen GJ; van Roon-Mom WM
    Neurol Sci; 2015 Mar; 36(3):429-34. PubMed ID: 25294428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Localization of rabbit huntingtin using a new panel of monoclonal antibodies.
    Wilkinson FL; Nguyen TM; Manilal SB; Thomas P; Neal JW; Harper PS; Jones AL; Morris GE
    Brain Res Mol Brain Res; 1999 May; 69(1):10-20. PubMed ID: 10350633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping of the epitope of monoclonal antibody 2B4 to the proline-rich region of human Huntingtin, a region critical for aggregation and toxicity.
    Dehay B; Weber C; Trottier Y; Bertolotti A
    Biotechnol J; 2007 May; 2(5):559-64. PubMed ID: 17373643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody.
    Colby DW; Chu Y; Cassady JP; Duennwald M; Zazulak H; Webster JM; Messer A; Lindquist S; Ingram VM; Wittrup KD
    Proc Natl Acad Sci U S A; 2004 Dec; 101(51):17616-21. PubMed ID: 15598740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.
    Lecerf JM; Shirley TL; Zhu Q; Kazantsev A; Amersdorfer P; Housman DE; Messer A; Huston JS
    Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4764-9. PubMed ID: 11296304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
    Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins.
    Ko J; Ou S; Patterson PH
    Brain Res Bull; 2001 Oct-Nov 1; 56(3-4):319-29. PubMed ID: 11719267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
    Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
    Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity.
    Khoshnan A; Ko J; Patterson PH
    Proc Natl Acad Sci U S A; 2002 Jan; 99(2):1002-7. PubMed ID: 11792860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PolyQ Antibodies Recognize a Short PolyQ Stretch in Both Normal and Mutant Huntingtin Exon 1.
    Owens GE; New DM; West AP; Bjorkman PJ
    J Mol Biol; 2015 Jul; 427(15):2507-2519. PubMed ID: 26047735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epitope mapping of monoclonal antibody 4C8 recognizing the protein huntingtin.
    Cong SY; Pepers BA; Roos RA; Van Ommen GJ; Dorsman JC
    Hybridoma (Larchmt); 2005 Oct; 24(5):231-5. PubMed ID: 16225422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential distribution of the normal and mutated forms of huntingtin in the human brain.
    Gourfinkel-An I; Cancel G; Trottier Y; Devys D; Tora L; Lutz Y; Imbert G; Saudou F; Stevanin G; Agid Y; Brice A; Mandel JL; Hirsch EC
    Ann Neurol; 1997 Nov; 42(5):712-9. PubMed ID: 9392570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation of a 40-kDa Huntingtin-associated protein.
    Peters MF; Ross CA
    J Biol Chem; 2001 Feb; 276(5):3188-94. PubMed ID: 11035034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal Huntingtin's polyglutamine stretch on CAG140 mouse model pathogenesis.
    Zheng S; Ghitani N; Blackburn JS; Liu JP; Zeitlin SO
    Mol Brain; 2012 Aug; 5():28. PubMed ID: 22892315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form.
    Trottier Y; Devys D; Imbert G; Saudou F; An I; Lutz Y; Weber C; Agid Y; Hirsch EC; Mandel JL
    Nat Genet; 1995 May; 10(1):104-10. PubMed ID: 7647777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin.
    Caron NS; Desmond CR; Xia J; Truant R
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14610-5. PubMed ID: 23898200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro.
    Ermak G; Hench KJ; Chang KT; Sachdev S; Davies KJ
    J Biol Chem; 2009 May; 284(18):11845-53. PubMed ID: 19270310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Making (anti-) sense out of huntingtin levels in Huntington disease.
    Evers MM; Schut MH; Pepers BA; Atalar M; van Belzen MJ; Faull RL; Roos RA; van Roon-Mom WM
    Mol Neurodegener; 2015 Apr; 10():21. PubMed ID: 25928884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment.
    Legleiter J; Lotz GP; Miller J; Ko J; Ng C; Williams GL; Finkbeiner S; Patterson PH; Muchowski PJ
    J Biol Chem; 2009 Aug; 284(32):21647-58. PubMed ID: 19491400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of post-mortem delay on N-terminal huntingtin protein fragments in human control and Huntington disease brain lysates.
    Schut MH; Patassini S; Kim EH; Bullock J; Waldvogel HJ; Faull RLM; Pepers BA; den Dunnen JT; van Ommen GB; van Roon-Mom WMC
    PLoS One; 2017; 12(6):e0178556. PubMed ID: 28570578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.